Tülin Öztürk
About
In The Last Decade
Tülin Öztürk
57 papers receiving 398 citations
Peers
Comparison fields: 5 of 72
- Pathology and Forensic Medicine 110
- Surgery 85
- Pulmonary and Respiratory Medicine 83
- Oncology 71
- Molecular Biology 70
Countries citing papers authored by Tülin Öztürk
This map shows the geographic impact of Tülin Öztürk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tülin Öztürk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tülin Öztürk more than expected).
Fields of papers citing papers by Tülin Öztürk
This network shows the impact of papers produced by Tülin Öztürk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tülin Öztürk. The network helps show where Tülin Öztürk may publish in the future.
Co-authorship network of co-authors of Tülin Öztürk
This figure shows the co-authorship network connecting the top 25 collaborators of Tülin Öztürk. A scholar is included among the top collaborators of Tülin Öztürk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tülin Öztürk. Tülin Öztürk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 2 | |
| 6 | 1 | |
| 7 | 1 | |
| 8 | 9 | |
| 9 | 4 | |
| 10 | 2 | |
| 11 | PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. | 5 |
| 12 | 1 | |
| 13 | Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population. | 7 |
| 14 | 3 | |
| 15 | 8 | |
| 16 | 6 | |
| 17 | 2 | |
| 18 | 41 | |
| 19 | 15 | |
| 20 | CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility. | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.